首页 > 最新文献

Diabetes/Metabolism Research and Reviews最新文献

英文 中文
Body Composition and Regional Adiposity in Adolescents With Type 1 Diabetes: Relation to Insulin Resistance, Glycaemic Control and Vascular Complications 1型糖尿病青少年的体成分和局部肥胖:与胰岛素抵抗、血糖控制和血管并发症的关系
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-04-04 DOI: 10.1002/dmrr.70041
Safinaz Adel Elhabashy, Bassma Abdelnasser Abdelhaleem, Sherihane Saieed Madkour, Christein Monir Kamal, Nouran Yousef Salah

Aim

Obesity is increasingly recognized among people with type 1 diabetes mellitus (T1DM). Little is known about the body composition of adolescents with T1DM and its metabolic outcomes. Hence, this study assessed the body composition of adolescents with T1DM and its relationship with glycaemic control, insulin resistance and vascular complications.

Materials and Methods

One hundred twenty adolescents with T1DM were assessed for anthropometric measures, insulin therapy, bioelectrical impedance analysis (BIA), fasting lipids, glycated haemoglobin, with estimated glucose disposal rate (eGDR) calculation. Regional body fat quantification was performed via Magnetic resonance imaging (MRI) 3-T.

Results

Thirty-three adolescents with T1DM were overweight (27.5%), and 8 were obese (6.6%). Adolescents with T1DM having insulin resistance were found to have significantly higher BMI z score, total body fat %, and visceral/subcutaneous fat % than those without insulin resistance (p < 0.05). Moreover, adolescents with T1DM having microvascular complications showed significantly higher total fat % and visceral/subcutaneous fat % than those without microvascular complications (p < 0.05). Visceral fat % and visceral/subcutaneous fat ratio were positively correlated with waist/hip ratio, eGDR and LDL level (p < 0.05). Waist/hip ratio and eGDR were the most significant independent variables associated with visceral fat % and visceral/subcutaneous fat ratio among adolescents with T1DM using multivariate regression analysis.

Conclusions

Overweight and visceral adiposity are frequently encountered among the studied adolescents with T1DM. Visceral adiposity is associated with insulin resistance, hyperlipidaemia and microvascular complications among adolescents with T1DM independent of glycaemic control and insulin dosage.

目的肥胖在1型糖尿病(T1DM)患者中得到越来越多的认识。对青少年T1DM患者的身体组成及其代谢结果知之甚少。因此,本研究评估了青少年T1DM患者的身体组成及其与血糖控制、胰岛素抵抗和血管并发症的关系。材料与方法对120例T1DM青少年患者进行人体测量、胰岛素治疗、生物电阻抗分析(BIA)、空腹血脂、糖化血红蛋白(gly糖化血红蛋白)评估,并计算葡萄糖处置率(eGDR)。通过磁共振成像(MRI) 3-T进行区域体脂量化。结果青少年T1DM超重33例(27.5%),肥胖8例(6.6%)。有胰岛素抵抗的T1DM青少年BMI z评分、全身脂肪百分比和内脏/皮下脂肪百分比明显高于无胰岛素抵抗的青少年(p <;0.05)。此外,有微血管并发症的青少年T1DM患者的总脂肪百分比和内脏/皮下脂肪百分比明显高于无微血管并发症的青少年(p <;0.05)。内脏脂肪%和内脏/皮下脂肪比与腰臀比、eGDR和LDL水平呈正相关(p <;0.05)。多因素回归分析显示,腰臀比和eGDR是青少年T1DM患者内脏脂肪%和内脏/皮下脂肪比最显著的独立变量。结论超重和内脏肥胖是青少年T1DM患者的常见症状。在青少年T1DM患者中,内脏脂肪与胰岛素抵抗、高脂血症和微血管并发症相关,与血糖控制和胰岛素剂量无关。
{"title":"Body Composition and Regional Adiposity in Adolescents With Type 1 Diabetes: Relation to Insulin Resistance, Glycaemic Control and Vascular Complications","authors":"Safinaz Adel Elhabashy,&nbsp;Bassma Abdelnasser Abdelhaleem,&nbsp;Sherihane Saieed Madkour,&nbsp;Christein Monir Kamal,&nbsp;Nouran Yousef Salah","doi":"10.1002/dmrr.70041","DOIUrl":"https://doi.org/10.1002/dmrr.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Obesity is increasingly recognized among people with type 1 diabetes mellitus (T1DM). Little is known about the body composition of adolescents with T1DM and its metabolic outcomes. Hence, this study assessed the body composition of adolescents with T1DM and its relationship with glycaemic control, insulin resistance and vascular complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>One hundred twenty adolescents with T1DM were assessed for anthropometric measures, insulin therapy, bioelectrical impedance analysis (BIA), fasting lipids, glycated haemoglobin, with estimated glucose disposal rate (eGDR) calculation. Regional body fat quantification was performed via Magnetic resonance imaging (MRI) 3-T.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-three adolescents with T1DM were overweight (27.5%), and 8 were obese (6.6%). Adolescents with T1DM having insulin resistance were found to have significantly higher BMI <i>z</i> score, total body fat %, and visceral/subcutaneous fat % than those without insulin resistance (<i>p</i> &lt; 0.05). Moreover, adolescents with T1DM having microvascular complications showed significantly higher total fat % and visceral/subcutaneous fat % than those without microvascular complications (<i>p</i> &lt; 0.05). Visceral fat % and visceral/subcutaneous fat ratio were positively correlated with waist/hip ratio, eGDR and LDL level (<i>p</i> &lt; 0.05). Waist/hip ratio and eGDR were the most significant independent variables associated with visceral fat % and visceral/subcutaneous fat ratio among adolescents with T1DM using multivariate regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overweight and visceral adiposity are frequently encountered among the studied adolescents with T1DM. Visceral adiposity is associated with insulin resistance, hyperlipidaemia and microvascular complications among adolescents with T1DM independent of glycaemic control and insulin dosage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Artificial Intelligence in the Diagnosis and Management of Metabolic Syndrome: A Comprehensive Review 人工智能在代谢综合征诊断和治疗中的应用综述
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-03-27 DOI: 10.1002/dmrr.70039
Jingjing Liu, Zhangdaihong Liu, Chang Liu, Hong Sun, Xiaoguang Li, Yang Yang

Background

Metabolic syndrome (MetS) is a progressive chronic pathophysiological state characterised by abdominal obesity, hypertension, hyperglycaemia, and dyslipidaemia. It is recognised as one of the major clinical syndromes affecting human health, with approximately one-quarter of the global population impacted. MetS increases the risk of developing cardiovascular diseases (CVDs), stroke, type 2 diabetes mellitus (T2DM), and diverse metabolic diseases. Early diagnosis of MetS could potentially reduce the prevalence of these diseases. However, care for the MetS population faces significant challenges due to (i) a lack of comprehensive understanding of the full spectrum of associated diseases, stemming from unclear pathophysiological mechanisms and (ii) frequent underdiagnosis or misdiagnosis of MetS in clinical settings due to inconsistent screening guidelines, limited medical resources, time constraints in clinical practice, and insufficient awareness and training. The increasing availability of healthcare and medical data presents opportunities to apply and innovate with artificial intelligence (AI) in addressing these challenges. This review aims to (i) summarise the spectrum of diseases associated with MetS and (ii) review the diverse AI models applied to MetS and metabolic syndrome-related diseases (MetSRD), where MetSRD collectively refers to diseases and conditions directly associated with MetS.

Methods

Our review consists of two phases. Initially, we conducted a literature review on MetS to narrow down the spectrum of MetSRD based on the strength of clinical evidence. We then used the terms ‘Metabolic Syndrome’ and ‘Machine Learning’ in combination with the identified MetSRD for further refinement. In total, we identified 52 related diseases in the first phase and 36 articles in the second phase.

Results

We identified a total of 52 MetSRD after the first phase, with T2DM, CVDs, and cancer being the top three. Among the 36 articles obtained in the second phase, we observed the following: (i) The criteria for MetS were inconsistent across the studies. (ii) The primary purpose of AI applications was to identify risk factors for diseases, thereby improving predictions for MetS or MetSRD. Traditional machine learning models, such as Random Forest and Logistic Regression, were found to be the most effective. (iii) In addition to the MetS criteria, AI models explored other factors, including demographic and physiological variables, dietary influences, lipidomic and proteomic indicators, and more.

代谢综合征(MetS)是一种进行性慢性病理生理状态,以腹部肥胖、高血压、高血糖和血脂异常为特征。它被认为是影响人类健康的主要临床综合症之一,全球约有四分之一的人口受到影响。MetS增加了患心血管疾病(cvd)、中风、2型糖尿病(T2DM)和多种代谢疾病的风险。早期诊断MetS可能潜在地降低这些疾病的患病率。然而,由于(i)不清楚的病理生理机制,对相关疾病的全谱缺乏全面的了解,以及(ii)由于不一致的筛查指南、有限的医疗资源、临床实践的时间限制以及认识和培训不足,在临床环境中经常误诊或误诊MetS,因此对MetS人群的护理面临着重大挑战。越来越多的医疗保健和医疗数据的可用性为应用和创新人工智能(AI)来应对这些挑战提供了机会。本综述旨在(i)总结与MetS相关的疾病谱,(ii)回顾应用于MetS和代谢综合征相关疾病(MetSRD)的各种人工智能模型,其中MetSRD统称为与MetS直接相关的疾病和病症。方法本研究分为两个阶段。最初,我们根据临床证据的强度对MetS进行了文献综述,以缩小MetSRD的范围。然后,我们将术语“代谢综合征”和“机器学习”与确定的MetSRD结合使用,以进一步细化。第一阶段共鉴定出52种相关疾病,第二阶段共鉴定出36篇相关文章。第一阶段后,我们共发现52例MetSRD,其中T2DM、cvd和癌症是前三名。在第二阶段获得的36篇文章中,我们观察到以下情况:(i)研究中MetS的标准不一致。㈡人工智能应用的主要目的是确定疾病的风险因素,从而改进对MetS或MetSRD的预测。传统的机器学习模型,如随机森林和逻辑回归,被发现是最有效的。(iii)除了MetS标准外,人工智能模型还探讨了其他因素,包括人口统计学和生理变量、饮食影响、脂质组学和蛋白质组学指标等。结论:本综述强调了MetS与一系列疾病之间的重要联系,特别关注未被报道的疾病,如非酒精性脂肪性肝病和中风。通过对来自不同来源的数据、人工智能模型和MetS诊断标准的分析,已经确定了传统措施之外的其他指标,强调了结合传统和非传统标志物以增强MetS和MetSRD诊断和预测能力的重要性。人工智能在MetS研究中显示出巨大的潜力,特别是通过整合多源数据,包括临床指标、遗传信息和组学数据。传统机器学习和现代机器学习模型的融合特别有前途,为模型性能和数据复杂性提供了一种平衡的方法。虽然国际定义具有全球适用性,但它们可能并不适用于所有人群和情景,因此需要灵活的诊断标准和自适应的、可解释的算法。最终,这些将使个性化诊断和有针对性的干预成为可能。
{"title":"Integrating Artificial Intelligence in the Diagnosis and Management of Metabolic Syndrome: A Comprehensive Review","authors":"Jingjing Liu,&nbsp;Zhangdaihong Liu,&nbsp;Chang Liu,&nbsp;Hong Sun,&nbsp;Xiaoguang Li,&nbsp;Yang Yang","doi":"10.1002/dmrr.70039","DOIUrl":"https://doi.org/10.1002/dmrr.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic syndrome (MetS) is a progressive chronic pathophysiological state characterised by abdominal obesity, hypertension, hyperglycaemia, and dyslipidaemia. It is recognised as one of the major clinical syndromes affecting human health, with approximately one-quarter of the global population impacted. MetS increases the risk of developing cardiovascular diseases (CVDs), stroke, type 2 diabetes mellitus (T2DM), and diverse metabolic diseases. Early diagnosis of MetS could potentially reduce the prevalence of these diseases. However, care for the MetS population faces significant challenges due to (i) a lack of comprehensive understanding of the full spectrum of associated diseases, stemming from unclear pathophysiological mechanisms and (ii) frequent underdiagnosis or misdiagnosis of MetS in clinical settings due to inconsistent screening guidelines, limited medical resources, time constraints in clinical practice, and insufficient awareness and training. The increasing availability of healthcare and medical data presents opportunities to apply and innovate with artificial intelligence (AI) in addressing these challenges. This review aims to (i) summarise the spectrum of diseases associated with MetS and (ii) review the diverse AI models applied to MetS and metabolic syndrome-related diseases (MetSRD), where MetSRD collectively refers to diseases and conditions directly associated with MetS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Our review consists of two phases. Initially, we conducted a literature review on MetS to narrow down the spectrum of MetSRD based on the strength of clinical evidence. We then used the terms ‘Metabolic Syndrome’ and ‘Machine Learning’ in combination with the identified MetSRD for further refinement. In total, we identified 52 related diseases in the first phase and 36 articles in the second phase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified a total of 52 MetSRD after the first phase, with T2DM, CVDs, and cancer being the top three. Among the 36 articles obtained in the second phase, we observed the following: (i) The criteria for MetS were inconsistent across the studies. (ii) The primary purpose of AI applications was to identify risk factors for diseases, thereby improving predictions for MetS or MetSRD. Traditional machine learning models, such as Random Forest and Logistic Regression, were found to be the most effective. (iii) In addition to the MetS criteria, AI models explored other factors, including demographic and physiological variables, dietary influences, lipidomic and proteomic indicators, and more.</p>\u0000 </section>\u0000 \u0000 ","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Benefits and Risks of Metabolic Surgery for Long-Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Trials 2型糖尿病超重/肥胖患者长期(5年)体重减轻和糖尿病缓解的代谢手术的获益和风险比较:随机试验的系统评价和网络荟萃分析
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-03-23 DOI: 10.1002/dmrr.70033
Xiaoyu Zang, Tong Lin, Jing Ma, Ying Zhang, Boxun Zhang, Yishan Huang, Danni Zhou, Lu Ding, Lili Zhang, Linhua Zhao

Background

While there have been studies comparing the efficiency of several metabolic operations in overweight or obese individuals with type 2 diabetes mellitus (T2DM), there is currently no comprehensive evidence about the complete remission of diabetes and its long-term safety.

Methods

This comprehensive review and network meta-analysis encompassed searches of many databases including PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, ClinicalTrials.gov, and Google Scholar. The search was conducted from the beginning of these databases’ existence until 1 May 2024. The study selected randomized controlled trials (RCTs) with a 5-year follow-up period to compare the clinical benefits and evaluate the occurrence of side events. The network meta-analysis employed a random-effects model. The registration number for PROSPERO is CRD42023412536.

Results

There was a total of 16 RCTs that included 1059 patients. A total of 897 patients, representing 84.7% of the entire sample, successfully completed the 5-year follow-up. Seven metabolic procedures were conducted. All ensuing estimates are to the comparison with a non-surgical treatment (NST). The evidence strongly supports that One-anastomosis gastric bypass (OAGB) is the most effective surgical procedure for achieving long-term complete remission of diabetes (relative risk [RR] 10.28, 95% CI 1.87 to 56.40). Additionally, Biliopancreatic diversion (BPD) is the most effective procedure for achieving long-term partial remission of diabetes (RR 16.74, 95% CI 4.66 to 60.12). The study found that BPD was the most successful method for long-term weight loss, with a mean difference of −11.68 in BMI decrease (95% CI −15.06 to −8.31) and a mean difference of −32.01 in weight change (95% CI −43.27 to −20.74). The evidence supporting this conclusion is of moderate quality. Regarding the occurrence of adverse events and complications related to surgery, gastrointestinal, macrovascular, and microvascular issues are not as frequent in BPD compared with NST (relative risk 0.29, 95% confidence interval 0.06 to 1.37). On the other hand, OAGB may have a higher occurrence of these difficulties, second only to BPD (relative risk 0.08, 95% confidence interval 0.2 to 3.29). Based on the findings on effectiveness and safety, it has been determined that OAGB (One Anastomosis Gastric Bypass) is more effective in obtaining long-term complete remission of diabetes and in assuring overall safety in diabetes management. However, BPD is superior to OAGB in terms of partial remission, weight loss and safety in diabetes management, ranking secon

虽然已经有研究比较了超重或肥胖2型糖尿病(T2DM)患者几种代谢手术的效率,但目前还没有关于糖尿病完全缓解及其长期安全性的全面证据。方法本综合综述和网络荟萃分析包括PubMed、Web of Science、Embase、Cochrane Central Register of Controlled Trials (Central)、Scopus、ClinicalTrials.gov和谷歌Scholar等多个数据库的检索。搜索从这些数据库存在之初一直进行到2024年5月1日。该研究选择随机对照试验(RCTs),随访5年,比较临床获益并评估副反应的发生。网络荟萃分析采用随机效应模型。普洛斯彼罗的注册号是CRD42023412536。结果共纳入16项rct,共纳入1059例患者。共897例患者成功完成5年随访,占整个样本的84.7%。进行了7个代谢过程。所有随后的估计是与非手术治疗(NST)的比较。证据有力地支持单吻合术胃旁路术(OAGB)是实现糖尿病长期完全缓解的最有效的手术方法(相对危险度[RR] 10.28, 95% CI 1.87 ~ 56.40)。此外,胆胰分流术(BPD)是实现糖尿病长期部分缓解最有效的手术(RR 16.74, 95% CI 4.66 - 60.12)。研究发现,BPD是最成功的长期减肥方法,BMI下降平均差值为- 11.68 (95% CI为- 15.06 ~ - 8.31),体重变化平均差值为- 32.01 (95% CI为- 43.27 ~ - 20.74)。支持这一结论的证据质量一般。关于与手术相关的不良事件和并发症的发生,与NST相比,BPD中胃肠道、大血管和微血管问题的发生率较低(相对危险度0.29,95%可信区间0.06 ~ 1.37)。另一方面,OAGB可能有更高的这些困难的发生率,仅次于BPD(相对风险0.08,95%置信区间0.2至3.29)。基于有效性和安全性的研究结果,已经确定OAGB(一次吻合胃旁路术)在获得糖尿病的长期完全缓解和确保糖尿病治疗的总体安全性方面更有效。然而,BPD在部分缓解、体重减轻和糖尿病管理的安全性方面优于OAGB,在这些方面排名第二。结论:BPD和OAGB在超重/肥胖T2DM患者实现长期体重减轻和糖尿病缓解方面均具有卓越的疗效。OAGB对于实现糖尿病的长期完全缓解尤其有利,总体上具有更高的安全性。研究发现,BPD对于长期糖尿病患者实现部分缓解和体重减轻是最有效的治疗方法,同时报告的副作用也最少。
{"title":"Comparison of Benefits and Risks of Metabolic Surgery for Long-Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Trials","authors":"Xiaoyu Zang,&nbsp;Tong Lin,&nbsp;Jing Ma,&nbsp;Ying Zhang,&nbsp;Boxun Zhang,&nbsp;Yishan Huang,&nbsp;Danni Zhou,&nbsp;Lu Ding,&nbsp;Lili Zhang,&nbsp;Linhua Zhao","doi":"10.1002/dmrr.70033","DOIUrl":"https://doi.org/10.1002/dmrr.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While there have been studies comparing the efficiency of several metabolic operations in overweight or obese individuals with type 2 diabetes mellitus (T2DM), there is currently no comprehensive evidence about the complete remission of diabetes and its long-term safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This comprehensive review and network meta-analysis encompassed searches of many databases including PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, ClinicalTrials.gov, and Google Scholar. The search was conducted from the beginning of these databases’ existence until 1 May 2024. The study selected randomized controlled trials (RCTs) with a 5-year follow-up period to compare the clinical benefits and evaluate the occurrence of side events. The network meta-analysis employed a random-effects model. The registration number for PROSPERO is CRD42023412536.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was a total of 16 RCTs that included 1059 patients. A total of 897 patients, representing 84.7% of the entire sample, successfully completed the 5-year follow-up. Seven metabolic procedures were conducted. All ensuing estimates are to the comparison with a non-surgical treatment (NST). The evidence strongly supports that One-anastomosis gastric bypass (OAGB) is the most effective surgical procedure for achieving long-term complete remission of diabetes (relative risk [RR] 10.28, 95% CI 1.87 to 56.40). Additionally, Biliopancreatic diversion (BPD) is the most effective procedure for achieving long-term partial remission of diabetes (RR 16.74, 95% CI 4.66 to 60.12). The study found that BPD was the most successful method for long-term weight loss, with a mean difference of −11.68 in BMI decrease (95% CI −15.06 to −8.31) and a mean difference of −32.01 in weight change (95% CI −43.27 to −20.74). The evidence supporting this conclusion is of moderate quality. Regarding the occurrence of adverse events and complications related to surgery, gastrointestinal, macrovascular, and microvascular issues are not as frequent in BPD compared with NST (relative risk 0.29, 95% confidence interval 0.06 to 1.37). On the other hand, OAGB may have a higher occurrence of these difficulties, second only to BPD (relative risk 0.08, 95% confidence interval 0.2 to 3.29). Based on the findings on effectiveness and safety, it has been determined that OAGB (One Anastomosis Gastric Bypass) is more effective in obtaining long-term complete remission of diabetes and in assuring overall safety in diabetes management. However, BPD is superior to OAGB in terms of partial remission, weight loss and safety in diabetes management, ranking secon","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Prediction Model for Predicting 10-year Incidence of Type 2 Diabetes in Japanese People; Panasonic Cohort Study 7 日本人10年2型糖尿病发病率预测模型的建立松下队列研究7
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-03-18 DOI: 10.1002/dmrr.70040
Chihiro Munekawa, Go Horiguchi, Akari Naito, Masahide Hamaguchi, Kazushiro Kurogi, Hiroaki Murata, Masato Ito, Akihiro Obora, Takao Kojima, Hiroshi Okada, Satoshi Teramukai, Michiaki Fukui

Aims

In Japan, several prediction models and scoring systems for type 2 diabetes have been reported; however, none have high utility. We developed a new clinical prediction model for the onset of type 2 diabetes.

Materials and Methods

The development dataset was obtained from 72,124 Japanese employees who participated in a health check-up programme conducted by Panasonic Corporation (Osaka, Japan), were aged 40 years or older, were diabetes-free at baseline, and followed-up for up to 10 years. The external validation dataset was obtained from 12,885 participants of the NAGALA (Gifu City, Gifu Prefecture Longitudinal Analysis) cohort. A prediction model was developed to predict the 10-year risk of developing diabetes using information from the health checkup programme. The developed model was internally validated, and externally validated using the NAGALA cohort.

Results

Using information on age, sex, body mass index, systolic blood pressure, log-triglycerides, high-density lipoprotein, log-alanine aminotransferase, fasting plasma glucose, weight gain, and smoking status obtained from a health checkup programme, we developed a novel, highly sensitive, and specific model for predicting the 10-year risk of developing diabetes. The prediction model showed excellent performance, with an optimism-corrected c-index of 0.877 and a c-index of 0.882 in the external validation cohort.

Conclusion

We developed a noninvasive diabetes risk-prediction model for the Japanese population and confirmed its utility for identifying individuals at high risk of type 2 diabetes over time.

在日本,已经报道了几种2型糖尿病的预测模型和评分系统;然而,它们都没有很高的效用。我们开发了一种新的2型糖尿病发病的临床预测模型。资料和方法研究数据来自72,124名日本员工,这些员工参加了松下公司(日本大阪)开展的健康检查项目,年龄在40岁或以上,基线时无糖尿病,随访时间长达10年。外部验证数据集来自NAGALA(岐阜市,岐阜县纵向分析)队列的12,885名参与者。利用健康检查项目的信息,建立了一个预测模型来预测10年内患糖尿病的风险。开发的模型进行了内部验证,并使用NAGALA队列进行了外部验证。结果:利用健康检查项目中获得的年龄、性别、体重指数、收缩压、甘油三酯、高密度脂蛋白、丙氨酸转氨酶、空腹血糖、体重增加和吸烟状况等信息,我们建立了一种新的、高度敏感的、特异性的模型,用于预测10年患糖尿病的风险。该预测模型表现优异,乐观校正后的c-index为0.877,外部验证队列的c-index为0.882。我们为日本人群建立了一种非侵入性糖尿病风险预测模型,并证实了其在识别2型糖尿病高风险个体方面的实用性。
{"title":"Development of a Prediction Model for Predicting 10-year Incidence of Type 2 Diabetes in Japanese People; Panasonic Cohort Study 7","authors":"Chihiro Munekawa,&nbsp;Go Horiguchi,&nbsp;Akari Naito,&nbsp;Masahide Hamaguchi,&nbsp;Kazushiro Kurogi,&nbsp;Hiroaki Murata,&nbsp;Masato Ito,&nbsp;Akihiro Obora,&nbsp;Takao Kojima,&nbsp;Hiroshi Okada,&nbsp;Satoshi Teramukai,&nbsp;Michiaki Fukui","doi":"10.1002/dmrr.70040","DOIUrl":"https://doi.org/10.1002/dmrr.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In Japan, several prediction models and scoring systems for type 2 diabetes have been reported; however, none have high utility. We developed a new clinical prediction model for the onset of type 2 diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The development dataset was obtained from 72,124 Japanese employees who participated in a health check-up programme conducted by Panasonic Corporation (Osaka, Japan), were aged 40 years or older, were diabetes-free at baseline, and followed-up for up to 10 years. The external validation dataset was obtained from 12,885 participants of the NAGALA (Gifu City, Gifu Prefecture Longitudinal Analysis) cohort. A prediction model was developed to predict the 10-year risk of developing diabetes using information from the health checkup programme. The developed model was internally validated, and externally validated using the NAGALA cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using information on age, sex, body mass index, systolic blood pressure, log-triglycerides, high-density lipoprotein, log-alanine aminotransferase, fasting plasma glucose, weight gain, and smoking status obtained from a health checkup programme, we developed a novel, highly sensitive, and specific model for predicting the 10-year risk of developing diabetes. The prediction model showed excellent performance, with an optimism-corrected c-index of 0.877 and a c-index of 0.882 in the external validation cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We developed a noninvasive diabetes risk-prediction model for the Japanese population and confirmed its utility for identifying individuals at high risk of type 2 diabetes over time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes 1型糖尿病青春期变化与内源性治疗之间的桥梁
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-03-11 DOI: 10.1002/dmrr.70038
M. A. Roma-Wilson, R. Buzzetti, S. Zampetti

The intersection of puberty with the onset of type 1 diabetes (T1D) presents unique pathogenic, clinical and psychosocial challenges, necessitating nuanced management strategies that account for developmental changes and the disease's heterogeneity. The distinction between pre-pubertal (T1DE1) and pubertal (T1DE2) T1D onset underscores the need for tailored approaches to monitoring and therapy during this critical period. Patients, with severe β-cell loss and heightened metabolic demands during puberty, require more intensive glycaemic management and screening for growth delays and pubertal disruptions. Meanwhile, pubertal T1D patients, though benefiting from relatively preserved β-cell function, still face heightened risks of insulin resistance and comorbidities such as obesity that demand vigilant monitoring and individualised interventions. Key actionable recommendations include implementing systematic screening protocols for growth impairment, menstrual abnormalities, and early markers of microvascular complications. Advanced technologies such as continuous glucose monitors and automated insulin delivery systems to reduce the glycaemic burden before and during puberty warrant robust investigation. The integration of behavioural interventions that enhance self-regulation and family-centred care into routine diabetes management can yield valuable insights into improving adherence and glycaemic control.

青春期与1型糖尿病(T1D)发病的交叉点呈现出独特的致病、临床和社会心理挑战,需要细致入微的管理策略,以解释发育变化和疾病的异质性。青春期前(T1DE1)和青春期(T1DE2) T1D发病的区别强调了在这一关键时期需要量身定制的监测和治疗方法。青春期严重β细胞损失和代谢需求增加的患者需要更严格的血糖管理,并筛查生长迟缓和青春期紊乱。同时,青春期T1D患者虽然受益于相对保存的β细胞功能,但仍然面临胰岛素抵抗和合并症(如肥胖)的高风险,需要警惕监测和个性化干预。关键的可行建议包括对生长障碍、月经异常和微血管并发症的早期标志物实施系统的筛查方案。先进的技术,如连续血糖监测仪和自动胰岛素输送系统,以减少青春期前和青春期期间的血糖负担,值得进行强有力的研究。将增强自我调节和以家庭为中心的护理的行为干预措施整合到常规糖尿病管理中,可以为改善依从性和血糖控制提供有价值的见解。
{"title":"Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes","authors":"M. A. Roma-Wilson,&nbsp;R. Buzzetti,&nbsp;S. Zampetti","doi":"10.1002/dmrr.70038","DOIUrl":"https://doi.org/10.1002/dmrr.70038","url":null,"abstract":"<p>The intersection of puberty with the onset of type 1 diabetes (T1D) presents unique pathogenic, clinical and psychosocial challenges, necessitating nuanced management strategies that account for developmental changes and the disease's heterogeneity. The distinction between pre-pubertal (T1DE1) and pubertal (T1DE2) T1D onset underscores the need for tailored approaches to monitoring and therapy during this critical period. Patients, with severe <i>β</i>-cell loss and heightened metabolic demands during puberty, require more intensive glycaemic management and screening for growth delays and pubertal disruptions. Meanwhile, pubertal T1D patients, though benefiting from relatively preserved <i>β</i>-cell function, still face heightened risks of insulin resistance and comorbidities such as obesity that demand vigilant monitoring and individualised interventions. Key actionable recommendations include implementing systematic screening protocols for growth impairment, menstrual abnormalities, and early markers of microvascular complications. Advanced technologies such as continuous glucose monitors and automated insulin delivery systems to reduce the glycaemic burden before and during puberty warrant robust investigation. The integration of behavioural interventions that enhance self-regulation and family-centred care into routine diabetes management can yield valuable insights into improving adherence and glycaemic control.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of an Advanced Hybrid Closed Loop System During Marathon Running: Case Examples and Clinical Implications 在马拉松比赛中使用先进的混合闭环系统:案例和临床意义
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-28 DOI: 10.1002/dmrr.70034
María T. Onetto, Denise Montt-Blanchard, Cari Berget, Kristel Strodhoff, Bruno Grassi

Background and aims

Maintaining glucose levels in the target range during aerobic training and athletic competition is especially difficult. The use of Automated Insulin Delivery (AID) technology is increasing, but exercise continues to be a challenge for persons with type 1 diabetes (T1D). In this case report series, we present 3 cases (C1, C2 and C3) of persons with T1D who used the MiniMed 780G during marathon races. We describe the strategies they used before, during and after the race to manage their glycaemia as well as the results of these strategies on their glycaemic control during the race.

Methods

The Medtronic CareLink platform was employed to remotely access insulin pump settings and glycaemic outcomes. Race parameters were obtained from sport watches. Supplemental data were obtained through interviews.

Results

Carelink data for Cases 1, 2, and 3 before the race were downloaded: Time in range (TIR) 70–180 mg/dL 89%, 76%, 82%; time above range (TAR) > 180 mg/dL, 9%, 20%, 16%; time below range (TBR) < 70 mg/dL, 1%, 4%, 1%, respectively. The breakfast insulin reduction percentages were −25%, 0%, and 0% for C1, C2, and C3, respectively. In all three cases, insulin dose reduction was applied to the pre-race snack at percentages of −50%, −100% and −83%. The consumption of carbohydrates during the race was 0.39 g/kg/hour, 0.42 g/kg/hour, and 0.5 g/kg/hour, respectively. The total amount of carbohydrates consumed was 101 g, 120 g, and 115 g, respectively. Throughout the race, a temporary target was used for all cases.

Conclusions

These cases provide insights for healthcare professionals who assist athletes with T1D using AID systems during prolonged physical activities. Highlighting the significance of specialised education, planning, and personalised approaches.

背景和目的在有氧训练和运动比赛中,将血糖水平维持在目标范围内是非常困难的。自动化胰岛素输送(AID)技术的使用正在增加,但运动仍然是1型糖尿病患者(T1D)的一个挑战。在本病例报告系列中,我们报告了3例(C1, C2和C3) T1D患者在马拉松比赛中使用MiniMed 780G的病例。我们描述了他们在比赛前、比赛中和比赛后使用的血糖控制策略,以及这些策略在比赛期间对血糖控制的效果。方法采用美敦力CareLink平台远程访问胰岛素泵设置和血糖结局。从运动手表中获得了比赛参数。通过访谈获得补充数据。结果:病例1、病例2和病例3在比赛前的Carelink数据下载:TIR范围(Time in range, TIR) 70 ~ 180 mg/dL 89%、76%、82%;超过范围时间(TAR) >;180 mg/dL, 9%, 20%, 16%;低于范围时间(TBR) <;70 mg/dL, 1%, 4%, 1%。C1、C2和C3的早餐胰岛素降低率分别为- 25%、0%和0%。在所有三种情况下,赛前零食的胰岛素剂量分别为- 50%,- 100%和- 83%。比赛期间碳水化合物的消耗量分别为0.39 g/kg/小时、0.42 g/kg/小时和0.5 g/kg/小时。摄入的碳水化合物总量分别为101克、120克和115克。在整个比赛过程中,所有情况都使用了一个临时目标。结论:这些病例为帮助T1D运动员在长时间体育活动中使用AID系统的医疗保健专业人员提供了见解。强调专业教育、规划和个性化方法的重要性。
{"title":"Use of an Advanced Hybrid Closed Loop System During Marathon Running: Case Examples and Clinical Implications","authors":"María T. Onetto,&nbsp;Denise Montt-Blanchard,&nbsp;Cari Berget,&nbsp;Kristel Strodhoff,&nbsp;Bruno Grassi","doi":"10.1002/dmrr.70034","DOIUrl":"https://doi.org/10.1002/dmrr.70034","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and aims</h3>\u0000 \u0000 <p>Maintaining glucose levels in the target range during aerobic training and athletic competition is especially difficult. The use of Automated Insulin Delivery (AID) technology is increasing, but exercise continues to be a challenge for persons with type 1 diabetes (T1D). In this case report series, we present 3 cases (C1, C2 and C3) of persons with T1D who used the MiniMed 780G during marathon races. We describe the strategies they used before, during and after the race to manage their glycaemia as well as the results of these strategies on their glycaemic control during the race.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Medtronic CareLink platform was employed to remotely access insulin pump settings and glycaemic outcomes. Race parameters were obtained from sport watches. Supplemental data were obtained through interviews.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Carelink data for Cases 1, 2, and 3 before the race were downloaded: Time in range (TIR) 70–180 mg/dL 89%, 76%, 82%; time above range (TAR) &gt; 180 mg/dL, 9%, 20%, 16%; time below range (TBR) &lt; 70 mg/dL, 1%, 4%, 1%, respectively. The breakfast insulin reduction percentages were −25%, 0%, and 0% for C1, C2, and C3, respectively. In all three cases, insulin dose reduction was applied to the pre-race snack at percentages of −50%, −100% and −83%. The consumption of carbohydrates during the race was 0.39 g/kg/hour, 0.42 g/kg/hour, and 0.5 g/kg/hour, respectively. The total amount of carbohydrates consumed was 101 g, 120 g, and 115 g, respectively. Throughout the race, a temporary target was used for all cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These cases provide insights for healthcare professionals who assist athletes with T1D using AID systems during prolonged physical activities. Highlighting the significance of specialised education, planning, and personalised approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143513808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal Trends in the Burden of Diabetes and Its Risk Factors Across the Western Pacific Region Between 1990 and 2044: A Systematic Analysis of the Global Burden of Disease Study 2019 1990年至2044年西太平洋地区糖尿病负担及其危险因素的时间趋势:对2019年全球疾病负担研究的系统分析
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-21 DOI: 10.1002/dmrr.70036
Xinwei Liu, Bing Wu, Yongqiang Lai, Xiyu Zhang, Hongyu Li, Fangqi Qu, Chenxi Zhang, Yulu Tian, Xuelian Fu, Jida Li, Huiqi Yang, Rui Chen, Baoguo Shi, Yanan Ma, Jia Meng, Ye Li

Aims

We aimed to assess changes in the burden of diabetes in the Western Pacific region (WPR) between 1990 and 2019, project future trends for 2020–2044, and identify the factors influencing these trends.

Materials and Methods

Data from the Global Burden of Disease Study 2019 were used to calculate the age-standardised incidence rate (ASIR), age-standardised death rate (ASDR) and age-standardised disability-adjusted life years (DALYs) rate for diabetes in the region. The Nordpred model was used to predict diabetes-related ASIR and ASDR trends over the next 25 years, and an age-period-cohort (APC) model analysed the effects of age, period and cohort. We examined the associations of ASIR, ASDR and age-standardised DALYs rate per 100,000 population with the socio-demographic index (SDI).

Results

We observed an increasing trend in the incidence. Mortality increased in the lower-middle income group and decreased slowly in the high- and upper-middle income groups. High body mass index significantly affected diabetes, with an increasing influence over time, whereas that of tobacco showed a decreasing trend. The incidence of diabetes showed a trend towards occurring at a younger age, in a manner consistent with the economic development trend. Diabetes incidence and mortality showed the opposite trend in the high-income group, with an increase in SDI.

Conclusions

The burden of diabetes is increasing in the WPR, in association with urbanisation and unhealthy lifestyles. Targeting the risk factors that affect all stages of the disease and managing them through multi-agency collaboration may improve the quality of life in patients living with the condition.

我们旨在评估1990年至2019年西太平洋地区(WPR)糖尿病负担的变化,预测2020年至2044年的未来趋势,并确定影响这些趋势的因素。材料和方法使用2019年全球疾病负担研究的数据计算该地区糖尿病的年龄标准化发病率(ASIR)、年龄标准化死亡率(ASDR)和年龄标准化残疾调整生命年(DALYs)率。Nordpred模型用于预测未来25年糖尿病相关ASIR和ASDR的趋势,年龄-时期-队列(APC)模型分析年龄、时期和队列的影响。我们研究了ASIR、ASDR和每10万人年龄标准化DALYs率与社会人口指数(SDI)的关系。结果观察到发病率呈上升趋势。中低收入群体的死亡率上升,而高收入和中高收入群体的死亡率下降缓慢。高体重指数对糖尿病的影响显著,且随着时间的推移而增加,而烟草对糖尿病的影响呈下降趋势。糖尿病发病率呈低龄化趋势,与经济发展趋势一致。糖尿病的发病率和死亡率在高收入人群中呈现相反的趋势,SDI增加。结论与城市化和不健康生活方式有关,WPR地区糖尿病负担正在增加。针对影响该疾病各个阶段的风险因素,并通过多机构合作对其进行管理,可能会改善患有该疾病的患者的生活质量。
{"title":"Temporal Trends in the Burden of Diabetes and Its Risk Factors Across the Western Pacific Region Between 1990 and 2044: A Systematic Analysis of the Global Burden of Disease Study 2019","authors":"Xinwei Liu,&nbsp;Bing Wu,&nbsp;Yongqiang Lai,&nbsp;Xiyu Zhang,&nbsp;Hongyu Li,&nbsp;Fangqi Qu,&nbsp;Chenxi Zhang,&nbsp;Yulu Tian,&nbsp;Xuelian Fu,&nbsp;Jida Li,&nbsp;Huiqi Yang,&nbsp;Rui Chen,&nbsp;Baoguo Shi,&nbsp;Yanan Ma,&nbsp;Jia Meng,&nbsp;Ye Li","doi":"10.1002/dmrr.70036","DOIUrl":"https://doi.org/10.1002/dmrr.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We aimed to assess changes in the burden of diabetes in the Western Pacific region (WPR) between 1990 and 2019, project future trends for 2020–2044, and identify the factors influencing these trends.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Data from the Global Burden of Disease Study 2019 were used to calculate the age-standardised incidence rate (ASIR), age-standardised death rate (ASDR) and age-standardised disability-adjusted life years (DALYs) rate for diabetes in the region. The Nordpred model was used to predict diabetes-related ASIR and ASDR trends over the next 25 years, and an age-period-cohort (APC) model analysed the effects of age, period and cohort. We examined the associations of ASIR, ASDR and age-standardised DALYs rate per 100,000 population with the socio-demographic index (SDI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We observed an increasing trend in the incidence. Mortality increased in the lower-middle income group and decreased slowly in the high- and upper-middle income groups. High body mass index significantly affected diabetes, with an increasing influence over time, whereas that of tobacco showed a decreasing trend. The incidence of diabetes showed a trend towards occurring at a younger age, in a manner consistent with the economic development trend. Diabetes incidence and mortality showed the opposite trend in the high-income group, with an increase in SDI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The burden of diabetes is increasing in the WPR, in association with urbanisation and unhealthy lifestyles. Targeting the risk factors that affect all stages of the disease and managing them through multi-agency collaboration may improve the quality of life in patients living with the condition.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inpatient Dietary Behaviour Score (IDBS) Predicts the Risk of Hypoglycemia in Type 2 Diabetes Mellitus (T2DM) Patients 住院患者饮食行为评分(IDBS)预测2型糖尿病(T2DM)患者低血糖的风险
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-14 DOI: 10.1002/dmrr.70035
Zhiping Liu, Jiangqiong Chen, Qing Liang, Wenjin Luo, Qingfeng Cheng, Qifu Li, Mei Mei, Liping Zan

Aims

The aim of this study was to develop the inpatient dietary behaviour score (IDBS) and validate its predictive performance in assessing the risk of hypoglycemia in patients with type 2 diabetes mellitus (T2DM).

Methods

The study included patients with T2DM admitted to the Endocrinology Department of the First Affiliated Hospital of Chongqing Medical University between 1 March 2021 and 1 March 2023. Patients were categorised into hypoglycemia and non-hypoglycemia groups using a paired approach, with hypoglycemia defined as any point-of-care glucose test results ≤ 3.9 mmol/L. Clinical data were collected, and the IDBS was calculated using a self-designed scale with 11 variables. Subsequently, measures for predicting hypoglycemia risk in hospitalised T2DM patients were formulated.

Results

A total of 1478 patients were included in the survey, with 739 patients in each of the hypoglycemic and non-hypoglycemic groups after pairing. Baseline differences were observed in education, marital status, job status, DM duration, glycosylated haemoglobin A1c (HbA1c), body mass index (BMI), hypoglycemia history, diabetic peripheral artery disease (DM-PAD), diabetic foot (DF), diabetic kidney disease (DKD), and diabetic retinopathy (DR) between the hypoglycemic and non-hypoglycemic groups. Significant correlations were found between the updated and baseline changes in the IDBS. The predictive efficacy was highest in DKD patients (OR = 1.82, 95% CI: 1.69–1.97, P = 6.75E-53). In multivariate analyses, only BMI, DM duration, diabetic foot and marriage response were included in the regression model. The area under the curve (AUC) and mean squared error (MSE) of the IDBS were 0.77 and 0.00039, respectively. A linear relationship existed between the IDBS and OR values, indicating that the risk of hypoglycemia increased with higher scores.

Conclusions

IDBS demonstrated a robust predictive effect on hypoglycemia. The variable data were easily obtainable, and the evaluation and calculation methods were straightforward. This scoring system could serve as a valuable reference for hypoglycemia prevention and screening of hospitalised diabetic patients at high risk of hypoglycemia.

目的本研究的目的是建立住院患者饮食行为评分(IDBS),并验证其在评估2型糖尿病(T2DM)患者低血糖风险中的预测作用。方法研究纳入2021年3月1日至2023年3月1日重庆医科大学第一附属医院内分泌科收治的T2DM患者。采用配对方法将患者分为低血糖组和非低血糖组,低血糖定义为任何护理点血糖试验结果≤3.9 mmol/L。收集临床资料,采用自行设计的包含11个变量的量表计算IDBS。随后,制定了预测住院T2DM患者低血糖风险的措施。结果共纳入1478例患者,配对后低血糖组和非低血糖组各739例。观察低血糖组与非低血糖组在教育程度、婚姻状况、工作状态、糖尿病病程、糖化血红蛋白A1c (HbA1c)、体重指数(BMI)、低血糖史、糖尿病外周动脉疾病(DM- pad)、糖尿病足(DF)、糖尿病肾病(DKD)、糖尿病视网膜病变(DR)等方面的基线差异。IDBS的更新和基线变化之间存在显著相关性。DKD患者的预测疗效最高(OR = 1.82, 95% CI: 1.69 ~ 1.97, P = 6.75E-53)。在多变量分析中,回归模型只包括BMI、糖尿病病程、糖尿病足和婚姻反应。IDBS曲线下面积(AUC)和均方误差(MSE)分别为0.77和0.00039。IDBS与OR值之间存在线性关系,表明低血糖的风险随着得分的增加而增加。结论IDBS对低血糖有较强的预测作用。变量数据容易获取,评价和计算方法简单。该评分系统可为低血糖预防和低血糖高危住院糖尿病患者的筛查提供有价值的参考。
{"title":"Inpatient Dietary Behaviour Score (IDBS) Predicts the Risk of Hypoglycemia in Type 2 Diabetes Mellitus (T2DM) Patients","authors":"Zhiping Liu,&nbsp;Jiangqiong Chen,&nbsp;Qing Liang,&nbsp;Wenjin Luo,&nbsp;Qingfeng Cheng,&nbsp;Qifu Li,&nbsp;Mei Mei,&nbsp;Liping Zan","doi":"10.1002/dmrr.70035","DOIUrl":"https://doi.org/10.1002/dmrr.70035","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aim of this study was to develop the inpatient dietary behaviour score (IDBS) and validate its predictive performance in assessing the risk of hypoglycemia in patients with type 2 diabetes mellitus (T2DM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included patients with T2DM admitted to the Endocrinology Department of the First Affiliated Hospital of Chongqing Medical University between 1 March 2021 and 1 March 2023. Patients were categorised into hypoglycemia and non-hypoglycemia groups using a paired approach, with hypoglycemia defined as any point-of-care glucose test results ≤ 3.9 mmol/L. Clinical data were collected, and the IDBS was calculated using a self-designed scale with 11 variables. Subsequently, measures for predicting hypoglycemia risk in hospitalised T2DM patients were formulated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1478 patients were included in the survey, with 739 patients in each of the hypoglycemic and non-hypoglycemic groups after pairing. Baseline differences were observed in education, marital status, job status, DM duration, glycosylated haemoglobin A1c (HbA1c), body mass index (BMI), hypoglycemia history, diabetic peripheral artery disease (DM-PAD), diabetic foot (DF), diabetic kidney disease (DKD), and diabetic retinopathy (DR) between the hypoglycemic and non-hypoglycemic groups. Significant correlations were found between the updated and baseline changes in the IDBS. The predictive efficacy was highest in DKD patients (OR = 1.82, 95% CI: 1.69–1.97, <i>P</i> = 6.75E-53). In multivariate analyses, only BMI, DM duration, diabetic foot and marriage response were included in the regression model. The area under the curve (AUC) and mean squared error (MSE) of the IDBS were 0.77 and 0.00039, respectively. A linear relationship existed between the IDBS and OR values, indicating that the risk of hypoglycemia increased with higher scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>IDBS demonstrated a robust predictive effect on hypoglycemia. The variable data were easily obtainable, and the evaluation and calculation methods were straightforward. This scoring system could serve as a valuable reference for hypoglycemia prevention and screening of hospitalised diabetic patients at high risk of hypoglycemia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis GLP-1受体激动剂与自杀意念和行为风险的关联:一项系统综述和荟萃分析
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-13 DOI: 10.1002/dmrr.70037
Ganesh Bushi, Mahalaqua Nazli Khatib, Shivam Rohilla, Mahendra Pratap Singh, Nidhi Uniyal, Suhas Ballal, Pooja Bansal, Kiran Bhopte, Manika Gupta, Abhay M. Gaidhane, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Ashish Singh Chauhan, Sanjit Sah, Hashem Abu Serhan, Muhammed Shabil

Background and Objective

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, providing metabolic and cardiovascular benefits. However, concerns have emerged about potential neuropsychiatric side effects, including suicidal ideation and behaviour, prompting investigations by regulatory bodies such as the FDA and EMA. This systematic review and meta-analysis aimed to assess the association between GLP-1RA use and the risk of suicidal ideation or behaviour.

Methods

A systematic literature search was conducted in PubMed, Embase, and Web of Science through September 2024, adhering to PRISMA guidelines. Observational cohort and case-control studies reporting suicidal ideation or behaviour in adults using GLP-1RAs were included. The Modified Newcastle-Ottawa Scale assessed risk of bias, and random-effect models calculated risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I2 statistic.

Results

Of 126 studies, 11 were included from multiple countries with diverse designs. The meta-analysis of four studies showed no statistically significant difference in suicidal outcomes between GLP-1RA users and users of other anti-hyperglycaemic drugs (RR: 0.568, 95% CI: 0.077–4.205). Substantial heterogeneity was observed (I2 = 98%). Pharmacovigilance studies indicated no disproportionate increase in suicidality, while some observational studies suggested a lower risk.

Conclusion

This review found no significant link between GLP-1RA use and increased suicidal ideation or behaviour. However, the high heterogeneity and reliance on pharmacovigilance data suggest caution. Clinicians should monitor patients, particularly those with psychiatric conditions, and further research is needed to assess long-term neuropsychiatric safety.

背景与目的胰高血糖素样肽-1受体激动剂(Glucagon-like peptide-1 receptor agonists, GLP-1RAs)广泛用于治疗2型糖尿病和肥胖症,具有代谢和心血管方面的益处。然而,对潜在的神经精神副作用的担忧已经出现,包括自杀意念和行为,促使FDA和EMA等监管机构进行调查。本系统综述和荟萃分析旨在评估GLP-1RA使用与自杀意念或行为风险之间的关系。方法按照PRISMA指南,于2024年9月在PubMed、Embase和Web of Science中进行系统的文献检索。报告使用GLP-1RAs的成人自杀意念或行为的观察性队列研究和病例对照研究被纳入。修正纽卡斯尔-渥太华量表评估偏倚风险,随机效应模型以95%置信区间(ci)计算风险比(RR)。采用I2统计量评估异质性。结果在126项研究中,有11项研究来自多个国家,采用不同的设计。四项研究的荟萃分析显示,GLP-1RA服用者与其他降糖药物服用者的自杀结局无统计学差异(RR: 0.568, 95% CI: 0.077-4.205)。观察到大量异质性(I2 = 98%)。药物警戒研究表明自杀率没有不成比例的增加,而一些观察性研究表明风险较低。结论:本综述未发现GLP-1RA使用与自杀意念或行为增加之间存在显著联系。然而,高度异质性和对药物警戒数据的依赖提示谨慎。临床医生应该监测患者,特别是那些有精神疾病的患者,并且需要进一步的研究来评估长期的神经精神病学安全性。
{"title":"Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis","authors":"Ganesh Bushi,&nbsp;Mahalaqua Nazli Khatib,&nbsp;Shivam Rohilla,&nbsp;Mahendra Pratap Singh,&nbsp;Nidhi Uniyal,&nbsp;Suhas Ballal,&nbsp;Pooja Bansal,&nbsp;Kiran Bhopte,&nbsp;Manika Gupta,&nbsp;Abhay M. Gaidhane,&nbsp;Balvir S. Tomar,&nbsp;Ayash Ashraf,&nbsp;M. Ravi Kumar,&nbsp;Ashish Singh Chauhan,&nbsp;Sanjit Sah,&nbsp;Hashem Abu Serhan,&nbsp;Muhammed Shabil","doi":"10.1002/dmrr.70037","DOIUrl":"https://doi.org/10.1002/dmrr.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, providing metabolic and cardiovascular benefits. However, concerns have emerged about potential neuropsychiatric side effects, including suicidal ideation and behaviour, prompting investigations by regulatory bodies such as the FDA and EMA. This systematic review and meta-analysis aimed to assess the association between GLP-1RA use and the risk of suicidal ideation or behaviour.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature search was conducted in PubMed, Embase, and Web of Science through September 2024, adhering to PRISMA guidelines. Observational cohort and case-control studies reporting suicidal ideation or behaviour in adults using GLP-1RAs were included. The Modified Newcastle-Ottawa Scale assessed risk of bias, and random-effect models calculated risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I<sup>2</sup> statistic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 126 studies, 11 were included from multiple countries with diverse designs. The meta-analysis of four studies showed no statistically significant difference in suicidal outcomes between GLP-1RA users and users of other anti-hyperglycaemic drugs (RR: 0.568, 95% CI: 0.077–4.205). Substantial heterogeneity was observed (I<sup>2</sup> = 98%). Pharmacovigilance studies indicated no disproportionate increase in suicidality, while some observational studies suggested a lower risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review found no significant link between GLP-1RA use and increased suicidal ideation or behaviour. However, the high heterogeneity and reliance on pharmacovigilance data suggest caution. Clinicians should monitor patients, particularly those with psychiatric conditions, and further research is needed to assess long-term neuropsychiatric safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia 糖尿病和胰岛素抵抗与脑健康在三个老龄化和痴呆协调队列研究中的关系综述
IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-28 DOI: 10.1002/dmrr.70032
Roshni Biswas, Ana W. Capuano, Rupal I. Mehta, Lisa L. Barnes, David A. Bennett, Zoe Arvanitakis

Diabetes increases the risk of dementia, and insulin resistance (IR) has emerged as a potential unifying feature. Here, we review published findings over the past 2 decades on the relation of diabetes and IR to brain health, including those related to cognition and neuropathology, in the Religious Orders Study, the Rush Memory and Aging Project, and the Minority Aging Research Study (ROS/MAP/MARS), three harmonised cohort studies of ageing and dementia at the Rush Alzheimer's Disease Center (RADC). A wide range of participant data, including information on medical conditions such as diabetes and neuropsychological tests, as well as other clinical and laboratory-based data collected annually. Neuropathology data are collected in participants who agree to autopsy at death. Recent studies have measured additional peripheral and brain IR data, including multi-omics. This review summarises findings from the RADC cohort studies that investigate the relation of diabetes and IR in older adults to cognition, neuropathology, omics in dementia, and other brain health measures. Examining the risk of clinically diagnosed dementia in older adults, our study found a 65% increased risk of Alzheimer's disease (AD) dementia in individuals with diabetes compared with those without. Regarding cognitive function, we have consistently observed associations of diabetes, as well as both peripheral and brain IR, with worse and declining performance in global cognition and specific cognitive domains, particularly semantic memory and perceptual speed. Studies utilising neuropathological data showed associations of diabetes and peripheral IR with brain infarcts, while brain IR measures, notably alpha serine/threonine-protein kinase1 (AKT1), were associated with both brain infarcts and AD pathology. Multi-omics studies suggested shared causal genes and pathways between diabetes and dementia. Recent epigenetic studies have revealed associations between IR and AD risk, along with distinct 5-hydroxymethylcytosine signatures in diabetes-associated AD. Furthermore, our studies have utilised other available data to investigate the impact of diabetes on neurological outcomes other than cognition and reported worsening of parkinsonian-like signs in diabetes. Recent studies have also explored risk factors for diabetes and have reported associations between lower literacy and decision-making abilities with elevated haemoglobin A1C levels, a peripheral IR measure. Overall, our findings, as summarised in this review, illustrate a range of mechanistic and other insights into the complex relationship of diabetes and IR with brain health. These findings may have important implications for future research on the ageing brain, including the prevention of cognitive decline and dementia in persons at risk for or with diabetes.

糖尿病增加痴呆的风险,而胰岛素抵抗(IR)已成为一个潜在的统一特征。在这里,我们回顾了过去20年来发表的关于糖尿病和IR与大脑健康关系的研究结果,包括与认知和神经病理学相关的研究结果,这些研究结果来自拉什阿尔茨海默病中心(RADC)的宗教秩序研究、拉什记忆和衰老项目和少数民族衰老研究(ROS/MAP/MARS),这三项关于衰老和痴呆的协调队列研究。广泛的参与者数据,包括关于糖尿病和神经心理测试等医疗状况的信息,以及每年收集的其他临床和实验室数据。神经病理学数据收集于同意在死亡时进行尸检的参与者。最近的研究测量了额外的外周和大脑红外数据,包括多组学。本综述总结了RADC队列研究的结果,这些研究调查了老年人糖尿病和IR与认知、神经病理学、痴呆组学和其他脑健康指标的关系。通过对老年人临床诊断为痴呆的风险进行检查,我们的研究发现,与没有糖尿病的人相比,糖尿病患者患阿尔茨海默病(AD)痴呆的风险增加了65%。关于认知功能,我们一直观察到糖尿病以及外周和大脑IR与整体认知和特定认知领域的表现恶化和下降有关,特别是语义记忆和感知速度。利用神经病理学数据的研究显示,糖尿病和外周IR与脑梗死有关,而脑IR测量,特别是α -丝氨酸/苏氨酸蛋白激酶(AKT1),与脑梗死和AD病理均相关。多组学研究表明,糖尿病和痴呆之间有共同的致病基因和途径。最近的表观遗传学研究揭示了IR与AD风险之间的关联,以及糖尿病相关AD中明显的5-羟甲基胞嘧啶特征。此外,我们的研究利用了其他可用的数据来调查糖尿病对认知以外的神经系统预后的影响,并报告了糖尿病中帕金森样症状的恶化。最近的研究也探讨了糖尿病的危险因素,并报道了低文化水平和决策能力与血红蛋白A1C水平升高(一种外周IR指标)之间的联系。总的来说,我们的研究结果,总结在这篇综述中,说明了糖尿病和IR与大脑健康的复杂关系的一系列机制和其他见解。这些发现可能对未来关于大脑老化的研究具有重要意义,包括预防有糖尿病风险或患有糖尿病的人的认知能力下降和痴呆。
{"title":"Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia","authors":"Roshni Biswas,&nbsp;Ana W. Capuano,&nbsp;Rupal I. Mehta,&nbsp;Lisa L. Barnes,&nbsp;David A. Bennett,&nbsp;Zoe Arvanitakis","doi":"10.1002/dmrr.70032","DOIUrl":"10.1002/dmrr.70032","url":null,"abstract":"<p>Diabetes increases the risk of dementia, and insulin resistance (IR) has emerged as a potential unifying feature. Here, we review published findings over the past 2 decades on the relation of diabetes and IR to brain health, including those related to cognition and neuropathology, in the Religious Orders Study, the Rush Memory and Aging Project, and the Minority Aging Research Study (ROS/MAP/MARS), three harmonised cohort studies of ageing and dementia at the Rush Alzheimer's Disease Center (RADC). A wide range of participant data, including information on medical conditions such as diabetes and neuropsychological tests, as well as other clinical and laboratory-based data collected annually. Neuropathology data are collected in participants who agree to autopsy at death. Recent studies have measured additional peripheral and brain IR data, including multi-omics. This review summarises findings from the RADC cohort studies that investigate the relation of diabetes and IR in older adults to cognition, neuropathology, omics in dementia, and other brain health measures. Examining the risk of clinically diagnosed dementia in older adults, our study found a 65% increased risk of Alzheimer's disease (AD) dementia in individuals with diabetes compared with those without. Regarding cognitive function, we have consistently observed associations of diabetes, as well as both peripheral and brain IR, with worse and declining performance in global cognition and specific cognitive domains, particularly semantic memory and perceptual speed. Studies utilising neuropathological data showed associations of diabetes and peripheral IR with brain infarcts, while brain IR measures, notably alpha serine/threonine-protein kinase1 (AKT1), were associated with both brain infarcts and AD pathology. Multi-omics studies suggested shared causal genes and pathways between diabetes and dementia. Recent epigenetic studies have revealed associations between IR and AD risk, along with distinct 5-hydroxymethylcytosine signatures in diabetes-associated AD. Furthermore, our studies have utilised other available data to investigate the impact of diabetes on neurological outcomes other than cognition and reported worsening of parkinsonian-like signs in diabetes. Recent studies have also explored risk factors for diabetes and have reported associations between lower literacy and decision-making abilities with elevated haemoglobin A1C levels, a peripheral IR measure. Overall, our findings, as summarised in this review, illustrate a range of mechanistic and other insights into the complex relationship of diabetes and IR with brain health. These findings may have important implications for future research on the ageing brain, including the prevention of cognitive decline and dementia in persons at risk for or with diabetes.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diabetes/Metabolism Research and Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1